Skip to main content

Table 4 Common AEs (occurring in 5 % of patients or more)a

From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

AE, n (%) Daclizumab 150 mg SC
(N = 410)
MS relapse 89 (22)
Nasopharyngitis 51 (12)
Upper respiratory tract infection 49 (12)
Increased ALT 37 (9)
Pharyngitis 35 (9)
Headache 33 (8)
Urinary tract infection 31 (8)
Back pain 29 (7)
Increased AST 28 (7)
Rash 27 (7)
Diarrhea 22 (5)
Allergic dermatitis 21 (5)
Viral respiratory tract infection 20 (5)
Bronchitis 19 (5)
Oral herpes 19 (5)
  1. AE Adverse event, ALT Alanine aminotransferase, AST Aspartate aminotransferase, MS Multiple sclerosis, SC Subcutaneous
  2. aAEs in ≥5 % of patients by Medical Dictionary for Regulatory Activities Preferred Term